Gliomate G2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The combination of these two agents provides complementary mechanisms to achieve effective blood glucose regulation in patients inadequately controlled by diet and exercise alone. Gliomate G2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as the risk of hypoglycemia due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Consultation with a healthcare professional is essential before initiating therapy to ensure appropriate use and monitoring.